## Overview

1	Introduction	1
2	Basic Tools in Medical Decision Making	7
3	Expected Utility, Risk Aversion and Prudence	21
4	Treatment Decisions Without Diagnostic Tests	41
5	Treatment Decisions with Diagnostic Tests	61
6	Treatment Decisions Under Comorbidity Risk	83
7	Optimal Strategy for Multiple Diagnostic Tests	99
8	The Optimal Cutoff Point of a Diagnostic Test	21
9	A Test's Total Value of Information	.43
10	Valuing Health and Life	61
11	Conclusion	91
Ref	erences	93
Ind	ev 1	97



## **Contents**

1	Introduction	1
	1.1 Outline	2
	1.2 Notes	4
	1.3 References	5
2	Basic Tools in Medical Decision Making	7
_	2.1 Prevalence, Incidence and Risk	
	2.2 Discriminatory Power and Prediction Values	
	2.3 Probability, Odds and Likelihood Ratio	
	2.4 Continuous Test Outcomes and Cutoff Points	14
	2.5 Notes	17
	2.6 Exercises	17
	2.7 References	19
	Z./ References	19
3	Expected Utility, Risk Aversion and Prudence	21
	3.1 Menu of Actions, States of Nature and Consequences	22
	3.2 The Elementary Utility Function and the Expected Utility Rule	23
	3.3 The Axiom of Independence and the Expected Utility Rule	26
	3.4 The OALY Concept	28
	3.5 Risk Aversion	30
	3.6 Prudence	33
	3.7 Notes	37
	3.8 Exercises	37
	3.9 References	38
4		
	4.1 The Treatment Decision Under Diagnostic Risk	
	4.1.1 The Critical Prevalence Rate	
	4.1.2 Risk Attitudes and the Treatment Decision	47
	4.1.3 Diagnostic Risk, Risk Aversion and the Severity of Illness	51

x Contents

	4.2 The Treatment Decision Under Therapeutic Risk	53
	4.2.1 The Critical Success Probability	53
	4.2.2 The Role of Risk Attitude	56
	4.3 Notes	57
	4.4 Exercises	57
	4.5 References	59
5	Treatment Decisions with Diagnostic Tests	61
	5.1 The Value of Information of a Diagnostic Test	62
	5.1.1 The Perfect Test	62
	5.1.2 The Imperfect Test	65
	5.2 Risk Attitude and the Test and Treatment Thresholds	71
	5.2.1 The Perfect Test	71
	5.2.2 The Imperfect Test	74
	5.3 Potential Harm from a Test	76
	5.4 Notes	79
	5.5 Exercises	79
	5.6 References	81
_	m ( (D !! H   C   1!!! D!)	0.2
6		83
	6.1 Prudence and the Critical Prevalence Rate	84
	6.2 Prudence and the Test and Treatment Decisions	89
	6.2.1 The Perfect Test	89
	6.2.2 The Imperfect Test	92
	6.3 Notes	96
	6.4 Exercises	96
	6.5 References	96
7	Optimal Strategy for Multiple Diagnostic Tests	99
	7.1 Choosing Among Two Tests	100
	7.2 Combining Two Tests	103
	7.3 Test and Treatment Thresholds for Composite Tests	106
	7.4 The Optimal Sequence of and Potential Harm from Testing	112
	7.5 Parallel or Sequential Testing?	116
	7.6 Cost-Benefit Analysis for Individual and Sequential Tests	116
	7.7 Notes	118
	7.8 Exercises	119
	7.9 References	120
~		
8		121
	8.1 Endogenous Test Characteristics	122
	8.2 The Optimal Cutoff Point	124
	8.3 Test and Treatment Thresholds and the Optimal Cutoff Point	129

Contents xi

	3.4 Multiple Tests with Endogenous Sensitivity and Specificity:	
	Triple-Test and Amniocentesis	131
	8.4.1 The ROC Curve of the Triple Test	132
	8.4.2 The Value of Information and Optimal Use of the Triple	
	Test with Amniocentesis	133
	8.4.3 Deciding on the Test Outcome	137
	8.5 Notes	141
	B.6 Exercises	141
	8.7 References	142
	5.7 References	174
9	A Test's Total Value of Information	143
	9.1 Exogenous Test Characteristics	144
	9.1.1 Performance as a Function of Prevalence Rate	144
	9.1.2 Overall Performance	146
		151
	9.1.3 A Social Perspective	
	9.2 Endogenous Test Characteristics	152
	9.2.1 Performance as a Function of Prevalence Rate	152
	9.2.2 Overall Performance	153
	9.3 Application to Prenatal Diagnostics	154
	9.3.1 Age-Specific Performance	154
	9.3.2 Overall Performance	156
	9.4 Notes	158
	9.5 Exercises	158
	9.6 References	159
10	Valuing Health and Life	161
	10.1 Treatment and Health	162
	10.2 Treatment and Survival	169
	10.3 The Value of Health and Life	175
	10.4 Optimal Allocation of Health Across Individuals	179
	10.4.1 The Health Model	179
	10.4.2 The Health-Survival Model	182
	10.4.3 The QALY Model	184
	10.5 Conclusion	186
	10.6 Notes	187
	10.7 Exercises	187
	10.8 References	188
	10.9 Appendix	189
	10.9 Appendix	107
11	Conclusion	191
11		
	11.1 References	192
D.	NAME OF THE OF T	102
ĸe	erences	193
Inc	***	197
THE	X	17/